180 related articles for article (PubMed ID: 35340619)
1. Four drug metabolism-related subgroups of pancreatic adenocarcinoma in prognosis, immune infiltration, and gene mutation.
Zhang T; Zhu L; Cai J; He J
Open Med (Wars); 2022; 17(1):427-440. PubMed ID: 35340619
[TBL] [Abstract][Full Text] [Related]
2. Mitophagy-mediated molecular subtypes depict the hallmarks of the tumour metabolism and guide precision chemotherapy in pancreatic adenocarcinoma.
Chen H; Zhang J; Sun X; Wang Y; Qian Y
Front Cell Dev Biol; 2022; 10():901207. PubMed ID: 35938160
[No Abstract] [Full Text] [Related]
3.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
4. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases.
Mao M; Ling H; Lin Y; Chen Y; Xu B; Zheng R
Front Genet; 2021; 12():702102. PubMed ID: 34335699
[TBL] [Abstract][Full Text] [Related]
5. Transmembrane Protein 170B is a Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic Adenocarcinoma.
Zhang Z; Shang J; Dai Z; Yao Y; Shi Y; Zhong D; Liang Y; Lai C; Yang Q; Feng T; Huang X
Front Genet; 2022; 13():848391. PubMed ID: 35601487
[No Abstract] [Full Text] [Related]
6. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
Wang C; Wang Z; Zhao Y; Jia R
BMC Gastroenterol; 2022 Nov; 22(1):495. PubMed ID: 36451085
[TBL] [Abstract][Full Text] [Related]
7. Construction of an RNA-Binding Protein-Related Prognostic Model for Pancreatic Adenocarcinoma Based on TCGA and GTEx Databases.
Wen X; Shao Z; Chen S; Wang W; Wang Y; Jiang J; Ma Q; Zhang L
Front Genet; 2020; 11():610350. PubMed ID: 33584809
[No Abstract] [Full Text] [Related]
8. A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma.
Wang H; Tian RF; Liang X; Fan J; Duan ZC; Fan XY; Zhang JJ; Yao DS; Chen ZN; Li L
Front Oncol; 2022; 12():1015042. PubMed ID: 36713541
[TBL] [Abstract][Full Text] [Related]
9. Construction of a ceRNA Network and Analysis of Tumor Immune Infiltration in Pancreatic Adenocarcinoma.
Xiao J; Lv C; Xiao C; Ma J; Liao J; Liu T; Du J; Zuo S; Li H; Gu H
Front Mol Biosci; 2021; 8():745409. PubMed ID: 34760926
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-Related Gene
Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
[TBL] [Abstract][Full Text] [Related]
11. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
Tian C; Li X; Ge C
Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
[TBL] [Abstract][Full Text] [Related]
12. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
14. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma.
Tang R; Zhang Y; Liang C; Xu J; Meng Q; Hua J; Liu J; Zhang B; Yu X; Shi S
PeerJ; 2020; 8():e9602. PubMed ID: 33062408
[TBL] [Abstract][Full Text] [Related]
15. Identification of methyltransferase modification genes associated with prognosis and immune features of pancreatic adenocarcinoma.
Wang W; Zhang D; Chang D; Li Y; Ren L
Mol Cell Probes; 2023 Feb; 67():101897. PubMed ID: 36740149
[TBL] [Abstract][Full Text] [Related]
16. An immune-related gene prognostic risk index for pancreatic adenocarcinoma.
Su Y; Qi R; Li L; Wang X; Li S; Zhao X; Hou R; Ma W; Liu D; Zheng J; Shi M
Front Immunol; 2022; 13():945878. PubMed ID: 35958614
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tumor microenvironment and programmed death-related genes to identify molecular subtypes and drug resistance in pancreatic cancer.
Yu L; He R; Cui Y
Front Pharmacol; 2023; 14():1146280. PubMed ID: 37007021
[No Abstract] [Full Text] [Related]
18. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms.
Yuan Q; Ren J; Wang Z; Ji L; Deng D; Shang D
Front Genet; 2021; 12():692953. PubMed ID: 34490033
[No Abstract] [Full Text] [Related]
19. Construction and validation of a RARRES3-based prognostic signature related to the specific immune microenvironment of pancreatic cancer.
Sun Y; Wang X; Yao L; He R; Man C; Fan Y
Front Oncol; 2024; 14():1246308. PubMed ID: 38375157
[TBL] [Abstract][Full Text] [Related]
20. Identification of an Autophagy-Related Pair Signature for Predicting Prognoses and Immune Activity in Pancreatic Adenocarcinoma.
Zhang Q; Lv L; Ma P; Zhang Y; Deng J; Zhang Y
Front Immunol; 2021; 12():743938. PubMed ID: 34956177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
